Erasca (ERAS)
(Delayed Data from NSDQ)
$3.07 USD
-0.03 (-0.97%)
Updated Sep 11, 2024 04:00 PM ET
After-Market: $3.08 +0.01 (0.33%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Erasca, Inc. [ERAS]
Reports for Purchase
Showing records 1 - 6 ( 6 total )
Company: Erasca, Inc.
Industry: Medical - Biomedical and Genetics
RAS Focus Expands with In-Licensing and Reprioritization: Reit. Buy and Lowering Our PT to $5
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Erasca, Inc.
Industry: Medical - Biomedical and Genetics
Multiple MAPK Catalysts May Provide Significant Upside in 2024; Reit Buy and $8 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Erasca, Inc.
Industry: Medical - Biomedical and Genetics
Naporafenib Leads MAPK Assault with Data in 2/4Q24; Reit. Buy and $8 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Erasca, Inc.
Industry: Medical - Biomedical and Genetics
Pipeline Progress and Prioritization Refine MAPK Assault Strategy; Reit Buy and Lowering Our PT to $8
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Erasca, Inc.
Industry: Medical - Biomedical and Genetics
Rich Catalyst Calendar Looks to Showcase an Assault on MAPK; Reit Buy and $10 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Erasca, Inc.
Industry: Medical - Biomedical and Genetics
An Oncogenic MAPK Assault on All Fronts; Initiating with a Buy Rating and $10 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
|